Dr. Eskelund on Study of TP53 Mutations in Mantle Cell Lymphoma

Christian Winther Eskelund, MD
Published: Saturday, Jun 24, 2017



Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma (MCL).

In a study of diagnostic samples from the Nordic trials (MCL2 and MCL3), the analysis showed that TP53 mutations were associated with significantly poorer outcome.

This study aimed to describe the impact and prevalence of TP53 and CDKN2A deletions in young patients with MCL.
 


Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma (MCL).

In a study of diagnostic samples from the Nordic trials (MCL2 and MCL3), the analysis showed that TP53 mutations were associated with significantly poorer outcome.

This study aimed to describe the impact and prevalence of TP53 and CDKN2A deletions in young patients with MCL.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x